Phase I/II Open-label Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the Autophagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Summary
The overall objective of this phase I/II study is to investigate the safety and preliminary efficacy of combination therapy with cobimetinib and hydroxychloroquine, with or without atezolizumab in patients with KRAS-mutated advanced malignancies.
General Information
NCT#: NCT04214418
Study ID: AAAS4165
Trial Phase: Phase I/II
Trial Sponsor: Genentech, Columbia University
Therapies Used in This Trial: Hydroxychloroquine, Cobimetinib, Atezolizumab